as of 03-23-2026 3:36pm EST
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 437.1M | IPO Year: | 2021 |
| Target Price: | $8.75 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.30 | EPS Growth: | 79.02 |
| 52 Week Low/High: | $0.46 - $3.07 | Next Earning Date: | 03-05-2026 |
| Revenue: | $53,426,000 | Revenue Growth: | 110.47% |
| Revenue Growth (this year): | 143.48% | Revenue Growth (next year): | 25.40% |
| P/E Ratio: | -4.60 | Index: | N/A |
| Free Cash Flow: | -58290000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Human Resources Officer
Avg Cost/Share
$1.58
Shares
20,964
Total Value
$33,077.00
Owned After
107,717
SEC Form 4
Chief Legal Officer, Secretary
Avg Cost/Share
$1.58
Shares
34,939
Total Value
$55,126.75
Owned After
181,736
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$1.58
Shares
20,964
Total Value
$33,077.00
Owned After
107,717
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$1.58
Shares
20,964
Total Value
$33,077.00
Owned After
117,717
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$1.58
Shares
19,392
Total Value
$30,596.70
Owned After
114,487
SEC Form 4
Chief Human Resources Officer
Avg Cost/Share
$1.54
Shares
19,663
Total Value
$30,273.15
Owned After
107,717
SEC Form 4
Chief Legal Officer, Secretary
Avg Cost/Share
$1.54
Shares
32,771
Total Value
$50,454.23
Owned After
181,736
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$1.54
Shares
19,663
Total Value
$30,273.15
Owned After
107,717
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$1.54
Shares
19,663
Total Value
$30,273.15
Owned After
117,717
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$1.54
Shares
18,189
Total Value
$28,003.78
Owned After
114,487
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Green Julie | IVVD | Chief Human Resources Officer | Feb 18, 2026 | Sell | $1.58 | 20,964 | $33,077.00 | 107,717 | |
| Andersen Jill | IVVD | Chief Legal Officer, Secretary | Feb 18, 2026 | Sell | $1.58 | 34,939 | $55,126.75 | 181,736 | |
| Duke William E. | IVVD | Chief Financial Officer | Feb 18, 2026 | Sell | $1.58 | 20,964 | $33,077.00 | 107,717 | |
| Lee Timothy Edward | IVVD | Chief Commercial Officer | Feb 18, 2026 | Sell | $1.58 | 20,964 | $33,077.00 | 117,717 | |
| Allen Robert D. III | IVVD | Chief Scientific Officer | Feb 18, 2026 | Sell | $1.58 | 19,392 | $30,596.70 | 114,487 | |
| Green Julie | IVVD | Chief Human Resources Officer | Feb 17, 2026 | Sell | $1.54 | 19,663 | $30,273.15 | 107,717 | |
| Andersen Jill | IVVD | Chief Legal Officer, Secretary | Feb 17, 2026 | Sell | $1.54 | 32,771 | $50,454.23 | 181,736 | |
| Duke William E. | IVVD | Chief Financial Officer | Feb 17, 2026 | Sell | $1.54 | 19,663 | $30,273.15 | 107,717 | |
| Lee Timothy Edward | IVVD | Chief Commercial Officer | Feb 17, 2026 | Sell | $1.54 | 19,663 | $30,273.15 | 117,717 | |
| Allen Robert D. III | IVVD | Chief Scientific Officer | Feb 17, 2026 | Sell | $1.54 | 18,189 | $28,003.78 | 114,487 |
SEC 8-K filings with transcript text
Mar 5, 2026 · 100% conf.
1D
-2.20%
$1.62
Act: +3.16%
5D
-14.98%
$1.41
20D
-4.18%
$1.59
8-K
false 0001832038 0001832038 2026-03-05 2026-03-05
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 5, 2026
Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter)
Delaware
001-40703
85-1403134
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
209 Church Street New Haven, CT
06510
(Address of Principal Executive Offices)
(Zip Code) Registrant’s telephone number, including area code: (781) 819-0080 Not applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 5, 2026, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025, and recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
Item 8.01. Other Events.
On March 5, 2026, the Company posted an updated corporate presentation on its website at www.invivyd.com. A copy of the presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release, dated March 5, 2026
99.2
Corporate Presentation, dated March 5, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 5, 2026
By:
/s/ Jill Andersen
Jill Andersen
Chief Legal Officer and Corporate Secretary
Jan 8, 2026 · 100% conf.
1D
-2.20%
$1.62
Act: +3.16%
5D
-14.98%
$1.41
20D
-4.18%
$1.59
8-K
false 0001832038 0001832038 2026-01-08 2026-01-08
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2026
Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter)
Delaware
001-40703
85-1403134
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
209 Church Street New Haven, CT
06510
(Address of Principal Executive Offices)
(Zip Code) Registrant’s telephone number, including area code: (781) 819-0080 Not applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 8, 2026, Invivyd, Inc. (the “Company”) issued a press release entitled “Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights” (the “Press Release”), which included the Company’s estimated fourth quarter 2025 PEMGARDA® (pemivibart) net product revenue and cash and cash equivalents as of December 31, 2025. The amounts included in the Press Release are preliminary and are subject to change upon completion of the Company’s financial closing controls and procedures for the quarter and year ended December 31, 2025, and finalization of the Company’s financial statements. The preliminary financial data included in the Press Release have been prepared by, and are the responsibility of, the Company’s management. These preliminary estimates have not been audited by the Company’s independent registered public accounting firm. Additional information and disclosures would be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 2.02.
Item 8.01 Other Events.
On January 8, 2026, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01. On January 8, 2026, the Company posted an updated corporate presentation on its website at www.invivyd.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference in this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release, dated January 8, 2026
99.2
Corporate Presentation, dated January 8, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 8, 2026
By:
/s/ Jill Andersen
Jill Andersen
Chief Legal Officer and Corporate Secretary
Nov 6, 2025
8-K
false 0001832038 0001832038 2025-11-06 2025-11-06
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2025
Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter)
Delaware
001-40703
85-1403134
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
209 Church Street
New Haven, CT
06510
(Address of Principal Executive Offices)
(Zip Code) Registrant’s telephone number, including area code: (781) 819-0080 Not applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 6, 2025, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025, and recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
Item 8.01. Other Events.
On November 6, 2025, the Company posted an updated corporate presentation on its website at www.invivyd.com. A copy of the presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release, dated November 6, 2025
99.2
Corporate Presentation, dated November 6, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 6, 2025
By:
/s/ Jill Andersen
Jill Andersen
Chief Legal Officer and Corporate Secretary
See how IVVD stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "IVVD Invivyd Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.